Healthcare provider profile · identity verified

Anusha Iyer, MD

Internal Medicine · KENT, WA · NPI 1942409388

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	402	115
Atorvastatin Calcium	Atorvastatin Calcium	341	107
Lisinopril	Lisinopril	276	78
Rosuvastatin Calcium	Rosuvastatin Calcium	269	82
Losartan Potassium	Losartan Potassium	216	59
Metoprolol Succinate	Metoprolol Succinate	186	52
Gabapentin	Gabapentin	146	41
Metformin Hcl	Metformin Hcl	131	34
Hydrochlorothiazide	Hydrochlorothiazide	129	44
Levothyroxine Sodium	Levothyroxine Sodium	129	39
Metformin Hcl Er	Metformin Hcl	118	36
Omeprazole	Omeprazole	109	39
Albuterol Sulfate Hfa	Albuterol Sulfate	101	24
Jardiance	Empagliflozin	89	23
Furosemide	Furosemide	79	28
Sertraline Hcl	Sertraline Hcl	79	26
Simvastatin	Simvastatin	79	24
Fluticasone Propionate	Fluticasone Propionate	73	22
Glipizide	Glipizide	72	22
Pravastatin Sodium	Pravastatin Sodium	69	21
Pantoprazole Sodium	Pantoprazole Sodium	65	24
Alendronate Sodium	Alendronate Sodium	64	20
Eliquis	Apixaban	64	17
Tamsulosin Hcl	Tamsulosin Hcl	64	19
Famotidine	Famotidine	61	15
Metoprolol Tartrate	Metoprolol Tartrate	60	17
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	57	19
Trazodone Hcl	Trazodone Hcl	56	18
Duloxetine Hcl	Duloxetine Hcl	51	16
Spironolactone	Spironolactone	44	15
Carvedilol	Carvedilol	43	13
Ozempic	Semaglutide	43	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	43	31
Mirtazapine	Mirtazapine	42	suppressed
Pregabalin	Pregabalin	40	suppressed
Diclofenac Sodium	Diclofenac Sodium	39	suppressed
Ezetimibe	Ezetimibe	38	11
Allopurinol	Allopurinol	36	12
Baclofen	Baclofen	33	suppressed
Atenolol	Atenolol	29	suppressed
Tizanidine Hcl	Tizanidine Hcl	29	13
Glimepiride	Glimepiride	28	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	28	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	27	suppressed
Ondansetron Hcl	Ondansetron Hcl	26	suppressed
Trueplus Insulin Syringe	Syringe And Needle,insulin,1ml	24	suppressed
Chlorthalidone	Chlorthalidone	23	suppressed
Clopidogrel	Clopidogrel Bisulfate	23	suppressed
Montelukast Sodium	Montelukast Sodium	21	suppressed
Meloxicam	Meloxicam	20	12
Metronidazole	Metronidazole	20	suppressed
Naproxen	Naproxen	20	11
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Potassium Chloride	Potassium Chloride	19	suppressed
Solifenacin Succinate	Solifenacin Succinate	19	suppressed
Valacyclovir	Valacyclovir Hcl	19	suppressed
Comfort Ez Pen Needle	Pen Needle, Diabetic	18	suppressed
Estradiol	Estradiol	18	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	18	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	17	16
Arnuity Ellipta	Fluticasone Furoate	17	suppressed
Hydrocortisone	Hydrocortisone	17	suppressed
Lovastatin	Lovastatin	17	suppressed
Lorazepam	Lorazepam	16	suppressed
Paroxetine Hcl	Paroxetine Hcl	16	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	15	suppressed
Humulin N	Insulin Nph Human Isophane	15	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	15	suppressed
Memantine Hcl	Memantine Hcl	15	suppressed
Mupirocin	Mupirocin	15	suppressed
Pro Comfort Alcohol Pads	Alcohol Antiseptic Pads	15	suppressed
Clobetasol Propionate	Clobetasol Propionate	14	suppressed
Hydralazine Hcl	Hydralazine Hcl	14	suppressed
Benazepril Hcl	Benazepril Hcl	13	suppressed
Ipratropium Bromide	Ipratropium Bromide	13	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	13	suppressed
Prednisone	Prednisone	13	suppressed
Valsartan	Valsartan	13	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Alprazolam	Alprazolam	11	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	11	suppressed
Methocarbamol	Methocarbamol	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error